Literature DB >> 22484322

Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision.

R N Lown1, B E Shaw.   

Abstract

The demand for unrelated haematopoietic cell (HPC) donors has risen threefold over the last decade, and is likely to continue to rise over the next 10 years. The time taken from diagnosis to transplant is recognised to adversely affect patient outcome, and provision of unrelated donors (UDs) has been identified as a key source of delay. Obstacles to provision of UD include: delays in referral to a transplant centre, awaiting sibling typing, lack of matched donors (particularly for those from ethnic minorities and/or with rare HLA phenotypes), low- or intermediate-resolution donor HLA typing, donor attrition from the registries, donor ineligibility on grounds of health and difficulties encountered transporting HPC across international borders. There are now over 18 million volunteer donors in registries worldwide, and efficiency has improved, at least in part, because of a switch from paper to electronic searches. As a result, the average time from search request to transplant is estimated to be less than half of what it was two decades ago. Furthermore, registries have developed a number of strategies designed to minimise delays and, ultimately, improve patient outcomes. These include: optimisation of donor numbers and ethnic mix through focused and selective recruitment; high-resolution typing at donor recruitment; cord blood banking with aggressive recruitment in ethnic minorities; early identification of those unlikely to find a match so alternative transplant options may be pursued in a timely manner, through use of HLA-based predictive algorithms; reduction of donor attrition; centralised, registry-based, donor identification services; and provision of a back-up donor.

Entities:  

Mesh:

Year:  2012        PMID: 22484322     DOI: 10.1038/bmt.2012.54

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

2.  Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients.

Authors:  Kazuhiro Ikegame; Katsuji Kaida; Satoshi Yoshihara; Masayuki Fujiwara; Kyoko Taniguchi; Ruri Kato; Takayuki Inoue; Tatsuya Fujioka; Hiroya Tamaki; Masaya Okada; Toshihiro Soma; Norihiko Kamikonya; Hiroh Saji; Shozo Hirota; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2012-05-25       Impact factor: 2.490

Review 3.  Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.

Authors:  Mary Eapen; Paul O'Donnell; Claudio G Brunstein; Juan Wu; Kate Barowski; Adam Mendizabal; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-23       Impact factor: 5.742

4.  Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation.

Authors:  Eric Davis; Sean Devlin; Candice Cooper; Melissa Nhaissi; Jennifer Paulson; Deborah Wells; Andromachi Scaradavou; Sergio Giralt; Esperanza Papadopoulos; Nancy A Kernan; Courtney Byam; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-26       Impact factor: 5.742

5.  Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Authors:  J Schetelig; M Schaich; K Schäfer-Eckart; M Hänel; W E Aulitzky; H Einsele; N Schmitz; W Rösler; M Stelljes; C D Baldus; A D Ho; A Neubauer; H Serve; J Mayer; W E Berdel; B Mohr; U Oelschlägel; S Parmentier; C Röllig; M Kramer; U Platzbecker; T Illmer; C Thiede; M Bornhäuser; G Ehninger
Journal:  Leukemia       Date:  2014-12-01       Impact factor: 11.528

Review 6.  Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?

Authors:  Martin Wermke; Silke Gloaguen; Uwe Platzbecker
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

7.  Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee.

Authors:  R N Lown; J Philippe; W Navarro; S M van Walraven; L Philips-Johnson; M Fechter; R Pawson; M Bengtsson; M Beksac; S Field; H Yang; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

8.  The increase of the global donor inventory is of limited benefit to patients of non-Northwestern European descent.

Authors:  Suzanna M van Walraven; Anneke Brand; Jack N A Bakker; Martin B A Heemskerk; Suzan Nillesen; Marc B Bierings; Laura B Bungener; Bouke G Hepkema; Arjan Lankester; Arnold van der Meer; Kees Sintnicolaas; Judith A E Somers; Eric Spierings; Marcel G J Tilanus; Christien E M Voorter; Jan J Cornelissen; Machteld Oudshoorn
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

9.  Outcomes of strategic alternative donor selection or suspending donor search based on Japan Marrow Donor Program coordination status.

Authors:  Naomi Kawashima; Satoshi Nishiwaki; Naoko Shimizu; Sonoko Kamoshita; Kyoko Watakabe; Emi Yokohata; Shingo Kurahashi; Yukiyasu Ozawa; Koichi Miyamura
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

10.  Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most.

Authors:  Bronwen E Shaw; Brent R Logan; Stephen R Spellman; Steven G E Marsh; James Robinson; Joseph Pidala; Carolyn Hurley; Juliet Barker; Martin Maiers; Jason Dehn; Hailin Wang; Mike Haagenson; David Porter; Effie W Petersdorf; Ann Woolfrey; Mary M Horowitz; Michael Verneris; Katharine C Hsu; Katharina Fleischhauer; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.